FirstIgnite is supporting the commercialization of the University of Montana’s berkeleylactone compounds technology. These new compounds have demonstrated potent antimicrobial activity, including an effective action against MRSA strains and other pathogens, and have a unique mode of action that sets them apart from other macrolide antibiotics.

This technology is applicable to the pharmaceutical industry, biotechnology research, and the healthcare sector. The global biotechnology market was worth $859.94 billion in 2022 and is projected to grow to $1,683.52 billion by 2030.

The University of Montana’s berkeleylactone compounds technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of Montana team, you can schedule a time directly on their team’s calendar here.